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Summary
Transgenic rats were created with overexpression of the Neu proto-oncogene in the mammary gland of both sexes, yet
only males developed mammary cancer in an androgen-dependent fashion. Transgenic females only developed mammary
cancer if treated with androgens. These tumors were positive for androgen receptor (AR), but negative for estrogen and
progesterone receptors. Extensive analysis failed to detect mutations anywhere within the neu transgene from mammary
carcinomas. Established mammary carcinomas eventually escaped their dependency on androgens. Transgenic long-term
gonadectomized rats did not develop mammary cancer, but Neu overexpression stimulated the growth of their mammary
glands. Our results suggest crosstalk between the Neu proto-oncogene and AR signaling pathways in the growth of both
the normal and cancerous mammary epithelium.
Introduction against Neu-overexpressing breast cancers (Cobleigh et al.,
1999; Slamon et al., 2001; Vogel et al., 2001). However, not all
women respond to these treatments, and the precise role thatNeu (also known as HER-2/ErbB-2) is one of four members in
a family of tyrosine kinase growth factor receptors that also Neu plays in the etiology of breast cancer remains poorly under-
stood. A critical question that remains unknown is whether Neuincludes HER-1/EGFR/ErbB-1, HER-3/ErbB-3, and HER-4/
ErbB-4. Comprehensive in vitro studies in cell lines have estab- is involved directly in the initiation of breast cancer or rather
instead only helps to drive cancer progression.lished that these four receptors form a complex array of homodi-
mers and heterodimers in response to ligand binding, with Neu Several rodent models have been developed to investigate
the role of Neu in breast cancer. The first transgenic (TG) miceserving as the preferred heterodimer binding partner for the
other three members. In particular, Neu stabilizes ErbB hetero- developed to study Neu utilized the mouse mammary tumor
virus long terminal repeat (MMTV LTR) to direct expression ofdimers, leading to enhanced mitogenic signaling (Yarden, 2001).
These in vitro experiments have solidified the importance of a mutated rat neu oncogene to the mammary gland (Bouchard
et al., 1989; Muller et al., 1988). The same mutated neu onco-Neu heterodimer formation in regulation of the ErbB signaling
network. In contrast, mutant-activated neu oncogenes predomi- gene also has been delivered to the mammary epithelium of
rats via infusion of recombinant retroviral vectors directly intonantly form Neu homodimers (Siegel et al., 1994; Siegel and
Muller, 1996; Yarden, 1990). the mammary duct in situ (Wang et al., 1991a). The neu onco-
gene used in these studies contains a single point mutation in theThe ErbB family has been associated with many different
human cancers. The connection between Neu and breast can- transmembrane domain (Bargmann et al., 1986), which results in
its constitutive dimerization and activation of the intrinsic tyro-cer has received the most attention. Slamon was the first to
show that neu gene amplification occurred in 25%–30% of sine kinase activity (Bargmann and Weinberg, 1988; Weiner
et al., 1989). In all of these rodent models, the activated neuhuman breast cancers and that this correlated with a poor pa-
tient prognosis (Slamon et al., 1987). Subsequent studies re- oncogene induced multiple mammary carcinomas. However, in
human breast cancer, activating mutations of neu have not beenvealed that the Neu protein also was overexpressed in the breast
carcinomas, correlating with gene amplification (Berger et al., found (Lemoine et al., 1990). The finding that human breast
cancer is associated with overexpression of only the nonmu-1988). Numerous clinical studies since then have consistently
found the same association between Neu overexpression and tated Neu proto-oncogene led to the development of additional
TG rodent models. The human neu proto-oncogene under thebreast cancer. Recently, there have been advances in the devel-
opment of monoclonal antibody therapies directed specifically control of the MMTV was used to generate both TG mice (Suda
S I G N I F I C A N C E
The contribution of Neu to the etiology of breast cancer is poorly understood. The novel transgenic rat model that we describe here
is a rodent model of the neu proto-oncogene that does not require somatic mutational activation of Neu to induce mammary
carcinomas. This finding is pertinent to human breast cancer, where Neu mutations are nonexistent. This report also shows an absolute
requirement for androgens in Neu-mediated mammary carcinogenesis. Our results potentially could lead to a greater understanding
of the mechanistic pathways that drive mammary carcinogenesis associated with Neu overexpression in both men and postmeno-
pausal women, for whom elevated testosterone is a strong risk factor for the disease.
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et al., 1990) and rats (Davies et al., 1998). However, in neither
case were mammary carcinomas induced by the transgene. In
the case of the TG rats, there was at most only a very low
expression of the transgene (Davies et al., 1998). The rat neu
proto-oncogene regulated by MMTV also has been used to
create TG mice (Guy et al., 1992). These female TG mice devel-
oped mammary carcinomas, but the total tumor burden was
much reduced and the latency was considerably longer com-
pared to mammary carcinogenesis in the activated neu TG mice
(Muller et al., 1988). A subsequent study, however, revealed
that at least 65% of the mammary carcinomas in the neu proto-
oncogene TG mice contained somatic deletion mutations within
the extracellular region of the neu transgene (Siegel et al., 1994).
The net effect of these mutations was constitutive homodimer-
ization and activation of Neu (Siegel and Muller, 1996), which
is functionally analogous to the transmembrane point mutation
studied in earlier models. Therefore, it remained to be shown
in an experimental rodent model whether the Neu proto-onco-
gene, when not associated with mutational activation, could
induce mammary cancer. Thus, we chose the rat to further
explore the possible role of the Neu proto-oncogene in the
etiology of mammary cancer. Rat mammary cancers, similar
to human cancers, display a wide spectrum of responses to
hormonal therapy (Wang et al., 1992). In addition, both rat and
human mammary cancers frequently are hormone dependent,
while murine mammary tumors are virtually all hormone inde-
pendent (Nandi et al., 1995). In this report, we describe the
generation and characterization of TG rats overexpressing the
rat Neu proto-oncogene in the mammary gland and the effects
of androgens in mediating mammary carcinogenesis.
Results
Figure 1. Determination of neu mRNA expression in a variety of tissues from
TG and NTG ratsGeneration of neu proto-oncogene TG rats
and distribution of neu mRNA expression A: Mammary glands were collected from young (78–82 days) or old (419–431
days) adult NTG or TG rats. Total RNA was isolated and the level of neuWe generated TG Sprague-Dawley rats using a construct con-
mRNA was determined from 4–6 rats/group following normalization to 18Staining the rat neu proto-oncogene cDNA under the control
rRNA using quantitative RT-PCR. The data is presented as the mean normal-
of the MMTV. A real-time RT-PCR assay based on TaqMan ized neu expression for each group plus SD. Data was compared between
chemistry was used to quantitatively assess the level of neu NTG and TG rats for each sex and age group, with an asterisk indicating
higher expression in TG rats (p 0.01). B: Testis (T), lung (LU), liver (LI), skeletalmRNA expression in a variety of tissues from TG rats or their
muscle (MU), and submaxillary salivary gland (SG) were collected fromnontransgenic (NTG) littermates. After normalization of the neu
young (78–81 days) adult males. Dorsolateral prostate (DLP), seminal vesiclelevels to 18S rRNA, the mean neu mRNA expression for each (SV), and coagulating gland (CG) were collected from old (419–425) adult
group was compared between TG and NTG tissues. neu mRNA males. Ventral prostate (VP) was collected from both young (YA) and old
levels were determined first in mammary glands from young (OA) adult males. Total RNA was isolated and the level of neu mRNA in
each tissue was determined following normalization to 18S rRNA using quan-(78–82 days) or old (419–431 days) adult male and female rats
titative RT-PCR from 2–3 rats/group (CG) or 3–4 rats/group (all other tissues).(Figure 1A). Both NTG males and females had little neu mRNA
The data is presented as the mean normalized neu expression for each
expression in the mammary gland at either age. Compared to group plus SD. Data was compared between NTG and TG rats for each
their NTG littermates, young TG males and females demon- tissue, with an asterisk indicating higher expression in TG rats (p  0.01).
strated 4.9-fold (p  0.004) and 1.4-fold (p  0.147) neu mRNA
overexpression, respectively, in the mammary gland. This over-
expression of neu mRNA was increased in the old TG rats, with
males and females expressing 10.9-fold (p  0.007) and 7.6-
tate (4.7-fold). With aging, neu mRNA expression in the TGfold (p  0.008) higher levels of neu, respectively, compared to
ventral prostate increased 2.2-fold (p  0.048). In all other tis-age-matched NTG rats. In the old TG mammary gland, neu
sues, there was no statistical difference in neu mRNA expressionmRNA was expressed at equivalent levels in the male and female
between TG and NTG males at a level of significance p  0.01.(p  0.219).
In addition to evaluating the female mammary gland for neuWe next evaluated whether neu mRNA was overexpressed
mRNA expression, we also analyzed neu mRNA levels in thein any other tissues of the TG male (Figure 1B). At a threshold
ovary of the young female rat. There was no difference in ovarianof p  0.01, there was neu mRNA overexpression in TG males
neu mRNA expression between TG and NTG females (p relative to NTG males in the lung (2.0-fold), dorsolateral prostate
(1.5-fold), young ventral prostate (2.3-fold), and old ventral pros- 0.070).
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no Neu expression. Cells expressing high levels of Neu were
clustered together as multicellular patches distributed heteroge-
neously throughout the gland. Among the young TG glands,
there was an apparent higher percentage of epithelial cells over-
expressing Neu in the male, compared to the female. However,
there was no difference in the intensity of Neu immunostaining
between the male and female glands. As a control, TG male
and female mammary glands were incubated with nonspecific
mouse IgG that demonstrated lack of any staining (Figures 2E
and 2F). Old TG males and females continued to express high
levels of Neu in the mammary epithelium (Figures 2G and 2H),
while old NTG rats had barely detectable amounts of the protein
(data not shown). Overall, there was an increase in the relative
ratio of mammary epithelial cells overexpressing Neu in the old
TG rats compared to the young animals. Western blotting for
Neu of whole-cell mammary gland lysates from TG rats con-
firmed expression of the protein (Figure 2I).
In contrast to the large overexpression of Neu within the TG
female mammary gland, the ovary, uterus, and cervix of TG
females did not overexpress Neu (data not shown).
Mammary carcinogenesis in the neu TG rat
is androgen dependent
Having demonstrated that the mammary glands of both TG
males and females produced elevated levels of Neu, we next
determined if long-term Neu overexpression would lead to
mammary cancer (Table 1). Untreated TG and NTG males and
females were palpated for the presence of mammary carcino-
mas beginning at approximately 9 months of age. All females
were maintained as virgins. By 419–434 days of age, two cohorts
of TG males demonstrated a mammary carcinoma incidence of
78% and 100%. Multiple mammary carcinomas arose in the
afflicted rats, with a mean of 3.0 and 4.9 mammary glands/rat
involved with tumor. By 496–587 days of age, all TG males had
developed multiple mammary carcinomas in approximately 6
glands/rat. Two TG male rats had gross metastatic lesions,
occurring in the lung, liver, kidney, intestines, and skull. For
male and female rats, complete necropsies were performed.
Interestingly, despite the overexpression of neu within the TG
prostate, no tumors were observed within this gland in either
intact or androgen-supplemented rats. In contrast to the TG
male, all TG females remained free of mammary cancer out to
Figure 2. Neu protein is overexpressed in the mammary gland of the neu
539 days of age. In addition, TG females did not develop cancersTG rat
of the ovary, uterus, or cervix, irrespective of their hormonalMammary gland sections were stained with a mouse monoclonal anti-Neu
status. Neither NTG males nor females developed mammary(A–D and G–H) or nonspecific mouse IgG (E and F). Samples were from
young (78–82 days, A–F) or old (419–431 days, G and H) adult rats. For TG carcinomas. Finally, there were no other gross or histological
and NTG rats, sections from 3–5 and 2 rats/group, respectively, were stained. pathologies in any of the rats due to the presence of the trans-
Representative results are shown from TG male (A, E, G), TG female (B, F, gene. Importantly, the mammary tumor induction in TG males
H), NTG male (C), and NTG female (D). The bar in A is 100 m and the same
was not associated with coincident pituitary tumors.scale was used for all panels. I: Whole cell lysates of TG rat mammary glands
We next evaluated the role of the hormonal environment inwere immunoblotted with a mouse monoclonal anti-Neu (top) or -tubulin
(bottom). controlling susceptibility to mammary carcinogenesis in the neu
TG rat (Table 1). Young adult TG males and females underwent
bilateral gonadectomy. NTG littermates were similarly treated.
All of the rats were sacrificed between 421 and 468 days of
The TG rat mammary gland overexpresses Neu protein age, approximately 1 year after gonadectomy. Orchidectomy
The mammary glands of TG and NTG rats also were compared completely prevented the development of mammary carcino-
utilizing immunohistochemistry with a mouse monoclonal anti- mas in all of the TG males, while ovariectomy of the TG female
body directed against Neu. In both young TG males and females, did not result in mammary cancer. All NTG rats were cancer-
there was clear Neu overexpression at the plasma membrane free. To verify that the absence of androgens was responsible for
of epithelial cells compared to the NTG (compare Figures 2A the inhibition of carcinogenesis, we reconstituted an androgenic
environment in gonadectomized TG and NTG males and fe-versus 2C and 2B versus 2D). Stromal cells displayed little to
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Table 1. Mammary carcinogenesis in the neu TG rat is androgen dependent
Hormonal Age at % rats with mammary Mean age to palpable Mean number glands
Genotype Sex status necropsy (days) n carcinomas carcinoma (days) with carcinomas
TG male intact 419–434 9 78 371  40.4 3.0  2.7
7 100 361  43.5 4.9  2.8
intact 496–587 3 100 427  45.2 6.0  0.0
17 100 nd 6.7  2.8
TG female intact 425–430 17 0 - -
530–539 4 0 - -
NTG male intact 420–433 17 0 - -
623–624 3 0 - -
NTG female intact 425–449 17 0 - -
530–539 6 0 - -
TG male orch 422–424 7 0 - -
TG female ovx 425–468 8 0 - -
NTG male orch 421–425 7 0 - -
NTG female ovx 427–431 8 0 - -
TG male orchDHT 397–438 10 100 338  55.2 7.3  2.0
TG male orchT 390–416 9 100 291  20.6 8.9  1.4
TG female ovxDHT 463–466 10 80 407  50.8 3.7  2.5
TG female ovxT 400–469 8 75 ** 3.4  2.6
NTG male orchDHT 432–450 10 0 - -
NTG male orchT 435–464 9 0 - -
NTG female ovxDHT 464–467 11 0 - -
NTG female ovxT 468–471 10 0 - -
TG female intact 430–446 8 0 - -
(biparous)
NTG female intact 427–446 13 0 - -
(biparous)
TG and NTG male and female rats were randomly divided into various treatment groups at 47–57 days of age. Females were kept as virgins or consecutively
mated twice as young adults (biparous). Mammary carcinomas were scored as palpable when they reach 3 mm in diameter. Double asterisk indicates
palpable tumors could not be accurately assessed due to the formation of numerous milk cysts. Mammary carcinoma data was collected at necropsy.
The data is presented as the group mean  SD. Abbreviations: orch, orchidectomy; ovx, ovariectomy; nd, not determined.
males by long-term treatment with either testosterone (T) or the mammary gland. At days 10–14 of pregnancy, neu mRNA levels
were elevated by 2.5-fold compared to the young virgin TGnonaromatizable androgen 5-dihydrotestosterone (DHT). We
did not examine the effects of androgen treatment on mammary female (data not shown). Therefore, we placed young females
through two consecutive full-term pregnancies and then sacri-carcinogenesis in intact female rats, because androgens induce
numerous changes to the rat ovary, including atrophy, cyst ficed them approximately 235 days after the second pregnancy
when they were an average of 439 days of age (Table 1). Despiteformation, and arrest of estrous (Burrows, 1949). These effects
would confound interpretation of the results. The rats were main- having a 4.5-fold higher level of neu mRNA expression com-
pared to the intact TG male, TG biparous females remainedtained continuously on androgens until sacrifice at 390–471
days of age. While androgen treatment did not induce mammary cancer-free. The effect of additional pregnancies beyond two
on mammary carcinogenesis was not investigated, due to ourtumors in any of the NTG rats, multiple mammary carcinomas
did develop in almost all of the TG rats. The incidence of carcino- experience that lactating Sprague-Dawley rats are susceptible
to developing ulcerating milk-filled lesions, which necessitatesmas among the males was 100%, irrespective of which andro-
gen was used. For the females, 75% and 80% of those treated sacrifice. These lesions are more likely to occur with increasing
number of pregnancies. However, it should be pointed out thatwith T and DHT, respectively, developed mammary carcinomas.
Radioimmunoassays of serum androgen levels at necropsy from an additional cohort of biparous TG females (n  4) were ob-
served for approximately 13 months after the first pregnancy.a subset of the rats showed that T implants resulted in a 2- to
3-fold elevation of T and a 2- to 4-fold elevation of DHT com- Therefore, this cohort experienced elevated neu expression lev-
els for a period of time equivalent to 13-month-old TG males,pared to the untreated male. DHT implants resulted in 12-fold
elevated DHT levels, while T was undetectable (0.1 ng/ml, in whom the mammary cancer incidence was approximately
data not shown). Androgen-treated gonadectomized male and 86% with numerous, large carcinomas in multiple glands. When
female rats had serum estradiol levels equal to that of the un- this group of biparous TG females was sacrificed at 558 days
treated male, and there were no appreciable differences in se- of age, there was only a single small mammary carcinoma in a
rum levels of T or DHT among similarly treated males and fe- single rat. However, spontaneous mammary cancers can be
males (data not shown). observed in normal female rats of advanced age.
Finally, we asked whether mammary carcinogenesis in the
TG female could be driven without androgen supplementation The neu transgene is amplified in mammary
carcinomasif neu expression was elevated to levels above that normally
found in the untreated TG female. We were able to show that Fluorescence in situ hybridization (FISH) was used to map the
transgene in lines 6500 and 2477. Metaphase chromosomalpregnancy stimulated neu mRNA expression in the TG female
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complete transgene as a probe. A single strong signal was
detected in 25%–40% of mammary carcinoma nuclei (Figures
3C and 3D). In comparison, normal mammary epithelium sur-
rounding the carcinoma displayed only a weak FISH signal in
20%–30% of the nuclei (Figure 3E, arrows). Hybridization with
the probe did not occur in mammary stromal fibroblasts and
vascular cells within the same sections. Also, testis from the
same cohort of TG males did not have detectable FISH signals
(Figure 3F). The endogenous neu gene was not detected in
interphase chromosomes, unlike in the lymphocyte metaphase
chromosomal preparation.
Mammary carcinogenesis is not associated with
somatic mutational activation of the neu
proto-oncogene in the neu TG rat
To assess if the mammary carcinomas arose due to somatic
mutational activation of the neu proto-oncogene as was found
in the neu TG mouse, the entire coding region of the neu trans-
gene was sequenced from five carcinomas from five individual
untreated TG males. Similarly, the complete neu transgene was
sequenced from three mammary carcinomas arising in orchid-
ectomized plus DHT-treated TG males and three carcinomas
from ovariectomized plus DHT-treated TG females. These carci-
nomas from DHT-treated rats were selected from three different
individual males and females. All of the mammary carcinomas
analyzed were completely free of mutations within the entire
neu coding region, regardless of sex or hormonal treatment.
Because the neu transgene was amplified in the carcinomas,
rare neu copies with mutations might remain undetected by
sequencing the pooled PCR-amplified transgene. To address
this, we therefore performed an extensive clonal sequence anal-
ysis of an approximately 750 bp region of the neu transgene
Figure 3. Chromosomal localization of the neu transgene and amplification spanning the transmembrane and adjacent extracellular do-in mammary carcinomas
main, which is a hotspot for mutations in the neu TG mouse.
Metaphase FISH was performed on spleen lymphocytes from TG males (A).
This region was PCR amplified using DNA from the same sixThe endogenous neu gene is shown on the telomeric end of chromosome
mammary carcinomas arising in DHT-treated gonadectomized10 (small arrow) (Koelsch, 1998), while the transgene of line 6500 was inte-
grated into the centromeric region of chromosome 10 (large arrow). DAPI TG males and females (three from each sex) that were com-
banding patterns are shown from the same metaphase preparation (B). pletely sequenced earlier. Because random mutations induced
Interphase FISH was conducted on paraffin-embedded tissue sections from by DNA polymerase were expected, we set criteria that a muta-mammary carcinomas (C and D), adjacent normal mammary epithelium
tion would only be considered “relevant” if it appeared in two(E), and testis (F) of TG males. The transgene signal was amplified in carci-
separate PCR reactions from the same carcinoma. Conse-noma compared to normal gland (E, arrows). No signal was detected in
testis. quently, for each carcinoma, two independent PCR reactions
were used, and the resulting PCR products were cloned. A total
of 54–66 individual clones from each PCR reaction (108–114
clones per carcinoma) was sequenced throughout the 750 bp
preparations from spleen lymphocytes of heterozygous TG neu fragment. A total of 465,038 bases was sequenced from 660
males at approximately 1 year of age were hybridized with a clones. There was a total of 125 mutated bases, representing
probe containing the entire transgene. The probe was able to 0.0269% of the total sequenced. This extremely small error rate
detect the endogenous neu gene on the telomeric region of is well within the expected error rate due to misincorporations
chromosome 10 (Figure 3A, small arrow). The signal intensity by DNA polymerase during PCR. No clones contained the pre-
of the endogenous neu gene was used to estimate the copy viously described activating point mutations within the trans-
number of the neu transgene. Line 6500 contained 3–6 copies membrane and adjacent extracellular domains that are associ-
of the transgene on chromosome 10q12 (Figure 3A, large arrow), ated with mammary carcinomas in the neu TG mice models.
while line 2477 had 1–2 transgene copies on the telomeric region Of the mutations that were found, only one (a C → T change
of chromosome 5 (data not shown). DAPI banding patterns of nucleotide 2137) was present in clones derived from both
identified the specific rat chromosomes containing positive inte- PCR reactions of the same tumor. However, this mutation did
grated FISH signals (Figure 3B). not result in a change of the encoding amino acid.
We next determined if mammary carcinomas in heterozy- We next investigated whether the somatic neu mutants
gous TG males displayed amplification of the neu transgene. found in the TG mouse were capable of inducing mammary
Interphase FISH was performed on two paraffin-embedded car- cancer in the rat if introduced into the gland exogenously. This
experiment was conducted to address the possibility that neucinomas from two untreated 14-month-old males using the
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mutations might be arising spontaneously in the untreated fe-
male gland but not leading to the formation of mammary carci-
nomas. Therefore, we subcloned the activated neu oncogenes
8142 and 8567 into a retroviral expression vector and introduced
retrovirus directly into the mammary gland ducts of 13–14 NTG
female rats. We could not test these retroviral constructs in the
male rat mammary gland, as the lack of nipples in the male rat
precludes ductal infusion. neu 8142 and 8567 are examples of
somatic constitutively active neu mutants containing deletions
in the extracellular domain that are responsible for mammary
carcinogenesis in the neu proto-oncogene TG mice (Siegel et
al., 1994). These deletion mutants were compared against the
previously characterized neu T, which contains a single activat-
ing point mutation in the transmembrane domain (Wang et al.,
1991a). As with neu T, both neu 8142 and neu 8567 served as
powerful oncogenes in the rat, rapidly transforming nearly all
of the infused mammary glands in 100% of the animals.
TG mammary carcinomas express Neu and AR
Mammary carcinomas from TG males and females were com-
pared histologically. All mammary carcinomas, irrespective of
sex or androgen treatment, had a uniform morphology con-
sisting of compact epithelium with a minimal amount of intratu-
moral stroma (Figures 4A and 4B). Occasionally, there was ex-
tensive invasion across the stromal capsule or into adjacent
skeletal muscle. Abundant levels of Neu with clear membrane
localization were confirmed in both male and female carcinomas
from lines 6500 and 2477 by immunohistochemistry (Figures
4C–4E). Normal mammary gland adjacent to the carcinomas
was always observed to have high Neu expression by immuno-
histochemistry. Quantitative comparison of neu mRNA levels in
the intact, untreated TG male between mammary carcinoma
(n  6) and normal mammary gland (n  4) revealed 12.6-fold
higher neu expression in the carcinomas (p  0.0003).
Expression of steroid hormone receptors in carcinomas from
untreated or orchidectomized DHT-treated males and ovariec-
tomized DHT-treated females were next determined by immu-
nohistochemistry. All analyzed carcinomas were completely
Figure 4. Mammary carcinomas in the neu TG rat express both Neu and ARnegative for both estrogen and progesterone receptor (ER, PR;
Mammary carcinoma sections from TG rats were stained with H&E (A anddata not shown). In contrast, epithelial expression of AR was
B), mouse monoclonal anti-Neu (C–E), rabbit polyclonal anti-AR (F, H, I), or
observed in 100% of the evaluated male carcinomas from both nonspecific rabbit IgG (G). Rat ventral prostate from an old adult NTG male
TG lines (Figure 4F and data not shown). Carcinomas incubated was stained for AR (J). Representative results are shown from multiple stained
sections. Mammary carcinomas displayed are from TG male of line 6500with nonspecific rabbit IgG demonstrated lack of nuclear stain-
that was untreated (A, C, F, G) or orch  DHT (H), untreated TG male ofing (Figure 4G). The status of AR also was assessed in carcino-
line 2477 (D), and TG female of line 6500 that was ovx  DHT (B, E, I). Themas from both males and females treated with DHT. In both
bar in A is 100m and the same scale was used for all panels. Abbreviations:
sexes, there was strong AR expression within the epithelial cells orch, orchidectomy; ovx, ovariectomy.
of the carcinomas (Figures 4H and 4I). Collectively, the mam-
mary carcinomas in the neu transgenic rat expressed levels of
AR close to that seen in the rat ventral prostate (Figure 4J).
serum levels of T were undetectable in both long-term gonadec-
Physiological levels of androgens are not necessary tomized TG males and females (0.1 ng/ml, data not shown).
for neu transgene expression Despite the absence of T, mammary gland expression of neu
We next addressed whether an intact hormonal environment mRNA in gonadectomized TG males and females was not statis-
was necessary for expression of the neu transgene regulated tically different from that of the intact, untreated TG male. This
by the MMTV. This was done to determine if the absence of suggests that other factors, such as glucocorticoids, are suffi-
mammary carcinomas in the gonadectomized TG rats was due cient to maintain high neu expression levels in the absence of
to loss of neu expression. Real-time RT-PCR was used to quan- androgens. In contrast to neu mRNA levels being unaffected by
tify the level of neu mRNA from mammary glands of old intact gonadectomy alone, gonadectomized TG rats given exogenous
and long-term gonadectomized rats. The mean neu mRNA ex- DHT demonstrated increased neu mRNA expression in the
pression from each group was plotted against the mean number mammary gland. Compared to their intact, untreated TG con-
trols, DHT-treated males had 2.7-fold (p  0.021) and DHT-of mammary glands with carcinomas (Figure 5). As expected,
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Figure 5. Physiological levels of androgens are not necessary for neu trans-
gene expression
Mammary glands were collected from old (419–468 days) TG rats. Females
were kept as virgins or consecutively mated twice as young adults (bipa-
rous), after which they remained untreated until the termination of the
experiment. Rats were kept intact or underwent bilateral gonadectomy 1
year prior to necropsy. Total RNA was isolated and the level of neu mRNA
was determined from 4–6 rats/group following normalization to 18S rRNA
using quantitative RT-PCR. The mean neu mRNA expression per group is
plotted against the mean number of mammary glands with carcinomas at
the time of necropsy. Horizontal and vertical error bars represent SD for the
mean neu mRNA expression and the mean number of mammary glands
with carcinomas, respectively. Note that female (intact), female (ovx), and
male (orch) are all actually at the zero point for the y axis. They are shown
separated for clarity purposes only. Abbreviations: orch, orchidectomy; ovx,
ovariectomy.
treated females had 3.6-fold (p  0.035) higher neu mRNA
expression.
We also determined levels of neu mRNA in the biparous
TG female mammary gland approximately 235 days after the
cessation of pregnancy. Compared to the intact, untreated TG
male, neu mRNA expression in the biparous TG female was
4.5-fold higher (p  0.033). This elevated level of neu mRNA
expression was similar to that of the DHT-treated female, yet
cancer did not arise in these biparous females. Overall, there
was no correlation between elevated levels of neu mRNA in the
various treatment groups and mammary carcinogenesis.
Neu overexpression substitutes for androgens in the Figure 6. Neu overexpression substitutes for androgens in maintenance of
maintenance of the male rat mammary gland morphology the male rat mammary gland morphology
Through histological analysis, we found that the morphology of Mammary gland sections from young (78–82 days; A–C, L) or old (419–467
the rat mammary gland is sexually dimorphic. The male mam- days; D–K) adult rats were stained with H&E (A–I) or mouse monoclonal
anti-Neu (J–L). Sections from at least four rats were evaluated for eachmary gland contains a high density of alveoli with solid nests
group. Representative results are shown from NTG intact male (A), NTGof epithelium devoid of a lumen (Figure 6A). In contrast, the
intact female (B), TG orch (for 1 month) male (C, L), NTG orch  DHT (forfemale mammary gland is made up of sparse alveoli with a single
1 year) male (D), NTG ovx  DHT (for 1 year) female (E), NTG orch (for 1
layer of epithelium arranged around a central lumen (Figure 6B). year) male (F), TG orch (for 1 year) male (G, J), NTG ovx (for 1 year) female
Mammary gland morphology did not differ between intact TG (H), and TG ovx (for 1 year) female (I, K). The bar in A is 100 m and the
same scale was used for all panels. Abbreviations: orch, orchidectomy; ovx,and NTG rats. Orchidectomy of young male rats resulted in
ovariectomy.dramatic morphological changes to the mammary gland in both
TG and NTG males (Figure 6C). The mammary epithelial content
was markedly reduced. This was accompanied by a loss of
central epithelium from the alveoli and the development of a tution of the androgenic environment with DHT completely re-
lumen. These morphological changes were established by 1 stored the mammary gland morphology to that of the intact
month after orchidectomy. These changes in the mammary epi- male (Figure 6D). Furthermore, females maintained on DHT also
gained a mammary morphology similar to that of the intact malethelium were proven to be due to androgen ablation, as reconsti-
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(Figure 6E). Both TG and NTG mammary glands were restored
by DHT treatment.
We next evaluated the effect of neu overexpression on mam-
mary gland morphology in the long-term gonadectomized TG
rats without androgen supplementation compared to age- and
treatment-matched NTG controls. One year after orchidectomy,
the mammary epithelium of all NTG male rats had persisted in a
severe, atrophied state (Figure 6F). However, in striking contrast,
the epithelial morphology of orchidectomized TG males had
been restored to that of the intact male (Figure 6G). Morphologi-
cal changes also were apparent in TG females. One year after
ovariectomy, the NTG female gland consisted largely of atro-
phied epithelium (Figure 6H). However, 63% (5/8) of the ovariec-
tomized TG females displayed partial conversion of the mam-
mary epithelium to that of an intact male (Figure 6I). In order to
determine if these changes to the mammary epithelium were
due to Neu overexpression, we performed immunohistochemis-
try on mammary gland sections from the long-term gonadecto-
mized rats. While the atrophic epithelium of the NTG rats was
negative for Neu expression (data not shown), the intact male-
like mammary epithelium of the gonadectomized TG males (Fig-
ure 6J) and females (Figure 6K) expressed abundant Neu. We
then evaluated Neu expression in the young TG males and
females 1 month after gonadectomy (Figure 6L and data not
shown). Although the epithelium was atrophied at this early
point after gonadectomy, in both sexes there was a small sub-
Figure 7. Mammary carcinomas in the neu TG rat acquire the ability to growpopulation of epithelial cells overexpressing Neu. The stimula-
in an androgen-depleted environmenttion of mammary epithelial growth in the long-term gonadecto-
A: Old TG males bearing at least one mammary carcinoma measuring 10mized TG males and females was independent of androgens,
mm in diameter underwent bilateral orch (at age indicated by the arrow)as all of the gonadectomized mammary glands were negative
and were regularly palpated for mammary carcinomas3 mm in diameter
for AR expression (data not shown). until necropsy at 602 days of age (n  8). The percentage of rats bearing
at least one carcinoma at each palpation time point was plotted against
the age of the rats in days. B: Total RNA was isolated from mammary carcino-Mammary carcinomas in the neu TG rat acquire the
mas of old TG males and the level of neu mRNA was determined afterability to grow in an androgen-depleted environment
normalization to 18S rRNA by quantitative RT-PCR. Carcinomas were col-
Two additional questions of interest were whether established lected from males that were untreated (intact), or orch for either 10 days
mammary carcinomas would display a strict androgen depen- (orch, 10 dy) or 6 months (orch, 6 mo). Five to six carcinomas from each
group were analyzed. The data is presented as the mean neu mRNA expres-dence for growth and whether Neu overexpression could pro-
sion for each group SD. C–F: Mammary carcinoma sections from TG malesmote the emergence of mammary cancer in an androgen-
were stained with mouse monoclonal anti-Neu (C and E), H&E (D), or rabbitdepleted environment. To address these issues, untreated TG
polyclonal anti-AR (F). Representative results are shown from at least 3–4
males with established mammary carcinomas underwent orchi- rats/group for orch, 10 dy (C) or orch, 6 mo (D–F). The bar in C is 100 m and
dectomy at 423–430 days of age. The rats were monitored by the same scale was used for all panels. Abbreviation: orch, orchidectomy.
palpation to ascertain the effects of orchidectomy on tumor
maintenance (Figure 7A). Complete regression was defined as
the point at which there were no palpable tumors. By 69 days
carcinomas. We further extended these findings by using immu-after orchidectomy, 75% of the rats had undergone complete
nohistochemistry to stain carcinomas for Neu expression 10regression with a mean time of 46 days. However, after a period
days (Figure 7C) or 6 months (Figure 7E) after orchidectomy.of time averaging 96 days without palpable lesions, tumors
These experiments confirmed that the carcinomas continuedbegan to reemerge. By the time the rats were 598–605 days of
age, which was approximately 6 months after orchidectomy, to express high levels of Neu in an androgen-depleted hormonal
the mammary carcinoma incidence was 88%, involving an aver- environment. We also assessed the AR status of the carcinomas
age of 1.4 mammary glands/rat. present 6 months after orchidectomy and all were found to
To verify that tumor regression was not simply a conse- be negative (Figure 7F). The histological morphology of these
quence of loss of neu, we performed real-time RT-PCR to mea- carcinomas did not differ from those present in intact, untreated
sure the level of neu mRNA in carcinomas from an additional males (Figure 7D).
cohort of rats 10 days following orchidectomy. By this time,
serum testosterone levels were undetectable (0.1 ng/ml, data Discussion
not shown), and many of the tumors were actively regressing.
The level of neu mRNA in these carcinomas was compared In this report, we describe a TG rodent model in which mammary
cancer arises due to overexpression of the nonmutated Neuwith those present 6 months after orchidectomy as well as
carcinomas in intact, untreated males (Figure 7B). Orchidectomy proto-oncogene. This contrasts with an earlier TG rat model of
the human neu proto-oncogene described by Davies et al., inhad no significant effect on neu mRNA expression within the
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which almost no mammary cancers arise in TG females. In a real-time RT-PCR assay to quantify the levels of neu mRNA
in the male and female mammary glands under various hormonaladdition, virgin female TG rats described by Davies et al. had
no transgene expression in the mammary gland (Davies et al., states. This analysis revealed that intact TG males and females
expressed equivalent amounts of neu mRNA at 419–434 days1999). This is a key difference with our neu TG females described
here, which display high Neu overexpression within the virgin of age, a time when nearly 100% of the males had multiple
mammary carcinomas. Furthermore, neu mRNA expression wasmammary gland. Davies et al. did not evaluate the mammary
glands of male TG rats, so it is not possible to compare our maintained at the same level as the intact male in long-term
gonadectomized rats of both sexes. In addition, the biparousfindings in neu TG males with those of theirs. However, the
absence of mammary cancers in the rats described by Davies female displayed a level of neu mRNA expression 4.5-fold higher
than even the intact TG male. These important findings led toet al. could likely be explained by their very low neu expression
in the mammary gland. In agreement with this hypothesis, we two conclusions. First, neu levels per se do not determine the
susceptibility of the mammary gland to carcinogenesis. Sec-have not observed mammary cancers in male or female TG rats
from several neu proto-oncogene TG lines that display very low ondly, physiological levels of androgens are not needed to main-
tain expression of the neu transgene. An implication from theseto nondetectable levels of neu in the mammary gland. These
observations imply that there might be a threshold level of neu experiments is that androgens serve a necessary function for
Neu-mediated mammary carcinogenesis apart from transcrip-overexpression required to induce mammary cancer.
We thoroughly searched for mutations within the neu trans- tional regulation of the MMTV LTR.
Consistent with this hypothesis, all of the mammary carcino-gene from mammary carcinomas from both untreated TG males
and rats of both sexes treated with DHT. Sequencing of the mas analyzed from males and females were AR positive but
were negative for both ER and PR. This makes it unlikely thatentire neu coding region from 11 carcinomas failed to find any
mutations in pooled PCR products. Because we found the neu either ER or PR is making a major contribution to mammary
carcinogenesis in the neu TG rat. This is consistent with humantransgene to be moderately amplified in mammary carcinomas,
we also analyzed 660 individual clones containing a fragment breast cancers, for which there is an inverse correlation between
ER, PR, and Neu overexpression (Berns et al., 1992; Ito et al.,of neu cloned from both TG male and female mammary carcino-
mas for mutations. This region of neu almost always contains 1995; Quenel et al., 1995; Zeillinger et al., 1989). Indeed, in
breast cancer cell lines, ER and Neu downregulate each otheroncogenic mutations in mammary carcinomas from the neu
proto-oncogene TG mouse (Siegel et al., 1994; Siegel and (Pietras et al., 1995; Read et al., 1990). These observations have
led to the general idea that Neu is preferentially associated withMuller, 1996). Despite our extensive searching, we did not find
any significant mutations. hormone-independent breast cancers. However, the potential
role of AR in breast carcinogenesis has received little attentionIn addition, we considered the possibility that activating
mutations might be arising in female rats but not leading to compared to ER and PR. This is despite the fact that AR expres-
sion has been demonstrated in 31%–85% of breast cancersmammary cancer. Therefore, activating neu deletion mutants
(Siegel et al., 1994) were introduced into the female rat mam- using a variety of methodologies (Allegra et al., 1979; Hall et
al., 1998; Isola, 1993; Lea et al., 1989; Miller et al., 1985). Fewmary gland via retroviral infusion to ask whether these neu mu-
tants could serve as oncogenes in the rat. Mammary cancer reports have evaluated associations between Neu and AR in
breast cancer (Isola, 1993; Kollara et al., 2001; Zeillinger etwas readily induced in 100% of the infused females, confirming
the potent oncogenicity of these Neu mutants in the rat mam- al., 1989). None of these studies found a positive correlation
between the two proteins. It is, however, difficult to draw firmmary gland. Therefore, since no mammary cancer spontane-
ously develops in the untreated neu proto-oncogene TG female conclusion from these reports as all consisted of relatively small
sample sizes.rat, we infer that these somatic activating deletion mutations
are not arising. Hence, our model shares an important attribute Nevertheless, we present evidence here that, in the neu TG
rat, there are interactions between the AR and Neu signalingwith human breast cancers, which are not associated with muta-
tional activation of the neu proto-oncogene (Lemoine et al., pathways that regulate growth of both the normal and cancerous
gland. In the normal, NTG rat, the male mammary gland was1990).
Although we used the same transgene construct to create found to be strictly dependent on physiological levels of andro-
gens to maintain its normal morphology. In addition, the normalour TG rats as that utilized by Muller and colleagues for produc-
tion of neu TG mice, we nevertheless observed striking pheno- female rat mammary epithelium underwent morphological tran-
sition to that of a male rat in response to long-term androgentypic differences from the mouse model. In the neu TG rat,
mammary carcinogenesis was androgen dependent and arose treatment. These observations underscore the critical role that
androgens serve in the normal rat mammary gland. An intriguingspontaneously only in the male. Significantly, carcinogenesis
could be induced in ovariectomized TG females, but only if they finding was that Neu overexpression in the TG male rat was able
to rescue mammary morphology after long-term orchidectomy.were treated with androgens. This is in complete contrast to
the neu TG mice, in which mammary carcinomas develop only This restoration occurred despite almost complete androgen
ablation. Even more surprising was the female-to-male morpho-in females and males have no lesions (Guy et al., 1992). The
male rat mammary cancer phenotype has been demonstrated logical conversion in the mammary glands of ovariectomized
TG females. Neu overexpression was not able to prevent initialin two independent TG lines (6500 and 2477), and in both lines
these cancers displayed expression of Neu and AR. Therefore, gonadectomy-induced mammary gland atrophy in the trans-
genic rats. However, the clear presence of a subpopulation ofthe novel phenotype that we describe here is not likely to be
simply a byproduct of a unique integration site for the transgene. epithelial cells overexpressing Neu in the young, gonadecto-
mized TG gland strongly suggests that these cells were impartedTo exclude the possibility of sex differences in transgene
expression accounting for the male-specific cancers, we used with a selective growth advantage, allowing for eventual mor-
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phological restoration with a minimal level of androgens. The observation that ovariectomized TG female rats treated with
androgens developed mammary cancer at high incidencecancerous mammary epithelium also benefited from Neu over-
expression in an androgen-depleted environment. Although means that this model could also help to clarify the role of
testosterone in postmenopausal female breast cancer. Severalmost of the mammary carcinomas were initially androgen de-
pendent and regressed in response to orchidectomy, mammary prospective clinical studies have shown that an elevated level
of testosterone is a major risk factor for breast cancer in post-cancers eventually reemerged several months after androgen
deprivation. menopausal women (Berrino et al., 1996; Cauley et al., 1999;
Dorgan et al., 1996; Thomas et al., 1997). Additionally, treatmentIn both the normal gland and the mammary cancers after
long-term gonadectomy, there was no detectable expression of both male (Liao et al., 1998) and female (Xie et al., 1999)
Noble rats with a combined regimen of testosterone and estro-of AR. Given the requirement for androgens in maintenance of
the epithelium following gonadectomy, these results suggest gen induced a high incidence of mammary cancer. Our model,
therefore, provides an additional tool to study the role of andro-that these growth-stimulatory effects of Neu are mediated in
part through the AR pathway in a process that is independent gens in breast cancer with the further advantage that coincident
estrogen treatment is not necessary for mammary carcinogen-of the receptor itself. As residual amounts of androgens remain
even after long-term orchidectomy, it is not possible to deter- esis.
In summary, the work that we present here could lead to amine from our data whether these are truly androgen-indepen-
dent mammary epithelial cells or rather are hypersensitive to greater understanding of the role of androgens in mediating
breast cancers in both men and women. In particular, it suggeststhe low levels of androgens that remain. However, the fact that
all of these mammary glands were negative for AR would sug- the need to extend these findings to a study of breast cancer
patients. It will be important in this study to examine the correla-gest the former, although more sensitive protein assays would
be needed to completely rule out the presence of AR. tion of serum androgen levels with the overexpression of Neu
in postmenopausal women with breast cancer.Our report shows interplay between the Neu and AR signal-
ing pathways within the mammary gland. Recently, it was re-
Experimental proceduresported that Neu and AR crosstalk in the prostate. Androgen-
independent xenografts spontaneously developed elevated Neu
Generation of TG rats
(Craft et al., 1999). In addition, forced overexpression of Neu Linearized plasmid encoding the rat neu proto-oncogene under the MMTV
in the androgen-dependent prostate cancer cell line LNCaP (pMMTVneuN) (Guy et al., 1992) was microinjected into the pronuclei of
resulted in the acquisition of androgen-independent transactiva- Sprague-Dawley single-cell zygotes. The technical aspects of generating
TG rats have been described (Charreau et al., 1996). Microinjections weretion of AR target genes and growth (Craft et al., 1999; Yeh et
performed by the Transgenic Animal Facility at the University of Wisconsin.al., 1999). Furthermore, this Neu-mediated AR transactivation
Of 12 founder lines generated, 10 displayed Mendelian inheritance. To date,was dependent upon a functional MAP kinase pathway (Yeh et
four lines have been evaluated. Lines 4311 and 6490 did not express the
al., 1999), which is a known downstream effector of Neu (Pinkas- transgene in either sex and were without phenotype. Two lines (6500, 2477)
Kramarski et al., 1996). Another group subsequently indicated overexpressed Neu in the male and female mammary gland, with develop-
Akt was also critical for Neu-AR crosstalk (Wen et al., 2000). ment of male mammary cancer. Line 6500 was further characterized. All
experiments are from line 6500 unless otherwise specified. TG rats used inSeveral clinical studies have corroborated the earlier in vitro
all experiments were heterozygous for the transgene. Screening for theexperiments. The percentage of prostate cancers overexpress-
transgene was performed by PCR using primers directed against the SV40ing Neu increased with clinical progression to androgen inde-
region of the transgene or neu. These primers did not amplify endogenouspendence (Osman et al., 2001; Shi et al., 2001; Signoretti et al.,
neu. SV40 primers were 5-ACTCCACACAGGCATAGAGTGTCTGC-3 and
2000). One report, however, failed to find such a relationship 5-AGGACACAGAGGAGCTTCCTGGGGAT-3. neu primers were 5-CGG
(Reese et al., 2001). Overall, the evidence to date strongly sup- AACCCACATCAGGCC-3 and 5-TTTCCTGCAGCAGCCTACGC-3.
ports the hypothesis that Neu is a key mediator in the evolution
Animal surgeries and hormone treatmentof androgen-independent prostate cancer. With the addition of
All protocols involving animals were approved by the Animal Care Committeeour findings here, we extend those observations first established
at the University of Wisconsin-Madison. Rats were gonadectomized by stan-in prostate cancer and suggest that interactions between Neu
dard surgical techniques. For androgen treatment, two 4 cm Dow Corning
and AR may be important in the etiology of a subset of breast Laboratory Grade Silastic tubes, i.d. 1.96 mm, o.d. 3.18 mm, (Fisher, Pitts-
cancers, and in particular with escape from androgen depen- burgh, PA) were filled with either T or 5-DHT (Sigma, St. Louis, MO) and
dency. sealed with Silicone Medical Adhesive (Factor II, Lakeside, AZ). The Silastic
Besides possible revelations into the mechanisms underly- tubes were implanted s.c. and replaced after 8 months.
ing Neu-mediated mammary carcinogenesis, the TG rats that
Real-time RT-PCRwe describe here could have more general applications in fur-
Frozen tissues were homogenized with a Polytron and total RNA was isolatedthering the understanding of breast cancer. It may be a useful
using the TRI Reagent (Molecular Research Center, Cincinnati, OH) ac-
model for male breast cancer, for which there are no well- cording to the manufacturer’s protocol. After treatment of the RNA with
characterized models. Although only 1% of breast cancers oc- DNA-free DNase I (Ambion, Austin, TX), two-step real-time quantitative RT-
cur in men (Ravandi-Kashani and Hayes, 1998), the disease PCR was performed on the ABI Prism 7700 Sequence Detector (Applied
Biosystems, Foster City, CA) using components from Applied Biosystems.generally results in a less favorable outcome compared to its
A multiplex TaqMan assay was run with simultaneous amplification of neufemale counterpart and is even less well understood. The fact
and 18S rRNA. For neu, the forward primer was 5-GCTGCTGCAGGAAACTthat Neu also is overexpressed in 17%–50% of male breast
GAGTTA-3 and the reverse primer was 5-CTGATCCAAGCACCTTCACcancers provides a further clinical connection between our
CTT-3. The neu TaqMan probe was 5-6FAM-ATGCCCAACCAGGCTCAG
model and the human male disease (Bruce et al., 1996; Dawson ATGCG-TAMRA-3 (Applied Biosystems). Primers and probes for 18S rRNA
et al., 1992; Joshi et al., 1996; Rayson et al., 1998; Shpitz were from the Ribosomal RNA Control Reagents (Applied Biosystems). Both
neu primers were used at a final concentration of 500 nM, while the neuet al., 2000; Temmim et al., 2001; Willsher et al., 1997). The
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probe was used at 125 nM. Each 18S rRNA primer was used at 50 nM and Approximately 750 bp of the neu insert was sequenced from multiple individ-
the 18S rRNA probe was at 200 nM. A cDNA standard curve was prepared ual clones using the primer 5-CTTTGGATCGGAGGCTGAT-3.
from rat kidney total RNA (Ambion). The relative level of neu mRNA expres-
sion was determined after normalization to 18S rRNA. Ductal infusion of retroviral neu mutant vectors
neu 8142 and neu 8567 from pJ4	neu8142 and pJ4	neu8567 (Siegel et
Histology and immunohistochemistry al., 1994) were subcloned into the retroviral expression vector pJR (Wang
Tissues were fixed in 10% neutral buffered formalin and routinely processed et al., 1991b). The construct JR/neu T was generated previously and reported
for histological analysis. After deparaffinization and rehydration, antigen un- as JR/neu (Wang et al., 1991a). The preparation of concentrated retroviral
masking was done by microwaving in Antigen Unmasking Solution (Vector stocks and ductal infusion into the rat mammary gland has been described
Laboratories, Burlingame, CA) for Neu, ER, and PR or 5 mM EDTA for AR. in detail (Thompson and Gould, 2000). All retroviral neu constructs were
Endogenous peroxidases were quenched by soaking the sections in 3% infused at a titer of 1 
 107 CFU/ml.
H2O2, followed by blocking in 10% horse or goat serum. Primary antibodies
and final concentrations used were mouse anti-Neu (Ab-17, NeoMarkers, Statistics
Fremont, CA) at 0.5 g/ml, mouse anti-ER (Ab-14, NeoMarkers) at 1:200, The level of neu gene expression was modeled using analysis of variance.
mouse anti-PR (Ab-10, NeoMarkers) at 5 g/ml, and rabbit anti-AR (N-20, Factorial models were fit to various subsets of the data. Likelihood ratio
Santa Cruz Biotechnology, Santa Cruz, CA) at 1 g/ml. Positive control tests were used to eliminate predictor variables that did not significantly
sections for ER were human breast carcinoma (NeoMarkers) and rat uterus improve the fit of the models. For significant main effects and interactions
and for PR were rat mammary carcinoma (NeoMarkers) and rat uterus. As with more than two levels, tests were conducted to assess pairwise differ-
a negative control, normal mouse or rabbit IgG was substituted for the ences. The response was transformed to the log scale before analysis to
primary antibody at an equal concentration for all experimental samples obtain approximately normally distributed residuals.
(Santa Cruz). Secondary antibodies and ABC Reagent were from the Vecta-
stain Elite ABC-Peroxidase Kit and used according to the manufacturer’s Acknowledgments
protocol (Vector Laboratories). Sections were developed using the DAB
Substrate Kit followed by counterstaining with VECTOR Methyl Green (Vector We thank William Muller (McMaster University) for supplying the plasmids
Laboratories). The slides were dehydrated and coverslips mounted with pMMTVneuN, pJ4	neu8142, and pJ4	neu8567, Joe Warren for performing
VectaMount mounting media (Vector Laboratories). the microinjections, Mary Lindstrom for statistical analysis, Jane Barnes
for rat surgeries, and Wendy Kennan for ductal infusions. This work was
SDS-PAGE and Western blotting supported in part by grants from the NIH (CA28954) and the Department of
Frozen mammary tissue was homogenized with a Polytron in 2 ml of ice- Defense (DOD-DAMD17-01-1-0459). P.A.W. was a recipient of a predoctoral
cold homogenization buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 2 mM fellowship from the Department of Defense (DOD-DAMD17-96-1-6263).
EDTA, 10 mM Na2HPO4, 10 mM Na4P2O7·10 H2O, 1% Triton X-100, 0.1%
SDS, 0.5% Na deoxycholate, 100 g/ml soybean trypsin inhibitor [Roche
Molecular Biochemicals, Indianapolis, IN], 1% Protease Inhibitor Cocktail Set
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